| VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases. We show 10 historical shares outstanding datapoints in our coverage of VYNE's shares outstanding history.|
Understanding the changing numbers of VYNE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VYNE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VYNE by allowing them to research VYNE shares outstanding history
as well as any other stock in our coverage universe.